HBV Treatment
EASL 2010: Tenofovir (Viread) Demonstrates High Barrier to Resistance over 3 Years in Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 23 April 2010 12:55
- Written by Liz Highleyman
No participants taking tenofovir (Viread) to treat chronic hepatitis B developed drug resistance through 144 weeks in 2 Phase 3 studies, according to a poster presentation last week at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) in Vienna. Researchers also reported that among patients who still had detectable HBV DNA at week 72, adding emtricitabine (Emtriva) did not reduce viral load more than tenofovir alone.
EASL 2010: Tenofovir/emtricitabine (Truvada) Prevents Hepatitis B Recurrence after Liver Transplantation in Patients with Mild Kidney Impairment
- Details
- Category: HBV Treatment
- Published on Tuesday, 20 April 2010 13:55
- Written by Liz Highleyman
Combination therapy using tenofovir (Viread) plus emtricitabine (Emtriva) -- the 2 drugs in the Truvada coformulation -- either with or without injected hepatitis B virus (HBV) antibodies, was well tolerated and prevented HBV recurrence in chronic hepatitis B patients with mild-to-moderate kidney (renal) impairment who underwent liver transplantation, according to a study presented last week at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) in Vienna.
Entecavir (Baraclude) Works Well in Patients with Adefovir-resistant Hepatitis B, but Lamivudine Resistance Compromises Efficacy
- Details
- Category: HBV Treatment
- Published on Friday, 02 April 2010 17:12
- Written by Liz Highleyman
The nucleoside analog entecavir (Baraclude) worked well in previously untreated chronic hepatitis B patients and in people who had developed resistance to the nucleotide analog adefovir (Hepsera), but did not perform well in people with resistance to lamivudine (Epivir-HBV) according to a European study described in the April 2010 Journal of Hepatology. Among patients who developed resistance to entecavir, tenofovir (Viread) remained an effective option.
Traditional Chinese Medicine May Perform Better than Interferon or Lamivudine for Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 06 April 2010 13:49
- Written by Liz Highleyman
Various traditional Chinese medicine (TCM) formulations were found to work as well as or better than the pharmaceutical drugs interferon and lamivudine for people with chronic hepatitis B, according to a joint U.S./Chinese review of clinical trials published in the February 2010 issue of Hepatology. While many of these studies were considered to be of poor quality according to Western drug testing standards, the review authors concluded that some TCM remedies appear effective and warrant further study.
Long-term Data Show Telbivudine (Tyzeka) Suppresses HBV Viral Load and Leads to HBeAg Clearance in Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 20 November 2009 00:00
- Written by Liz Highleyman
At the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) this month in Boston, researchers reported 4-year data from the GLOBE study, indicating that the nucleoside analog telbivudine (Tyzeka) continues to provide long-term viral load suppression, ALT normalization, and hepatitis B "e" antigen (HBeAg) seroconversion in chronic hepatitis B patients. Another study showed sustained response up to 2 years after completing telbivudine treatment.
More Articles...
- AASLD Issues Updated Practice Guidelines for Management of Chronic Hepatitis B
- Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B?
- Investigational 2-Dose Dynavax Heplisav Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine
- Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B
Web Design and Development by